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pxpression of Angiotensin II
eceptors in Human Left and Right
trial Tissue in Atrial Fibrillation With
nd Without Underlying Mitral Valve Disease
trial fibrillation (AF) causes various changes in atrial electrophys-
ology and morphology (1). Recently, an increased activity of the
trial angiotensin II (AngII) system was found in patients with AF
nd concomitant structural heart disease (SHD) (1–3). This
orresponds to an increased amount of atrial fibrous tissue. The
nitial trigger for activation of the AngII system typically is the
nderlying ventricular disease and not AF per se (1).
Boldt et al. (4) tried to analyze the expression of AngII receptors
ype 1 (AT1) and 2 (AT2) in patients with and without mitral valve
isease (MVD). The investigators claim that AT1 is upregulated in
brillating left atria, whereas AT2 remains unchanged. These
ndings are contrary to results from our group (3).
How can these differences be explained? When dealing with
eceptor expression in humans, defining “controls” is an important
ssue. This is especially true when determining the real impact of
he arrhythmia on angiotensin II receptor (AT) regulation, because
oncomitant heart diseases dramatically influence AngII levels.
oldt et al. (4) performed a pooled analysis using 74 left atrial
issue samples from patients with AF; 15 patients served as
matched” controls. Their analysis revealed, however, no differ-
nces at all in receptor expression between comparable patient
roups with MVD  chronic AF (cAF). Furthermore, patients
ith MVD and cAF are not different compared to patients with
HD in sinus rhythm (Fig. 5 in Boldt et al. [4]). The only
ifference, using an unpooled analysis, was between patients in SR
plus SHD) and patients with lone AF (Fig. 5 in Boldt et al. [4]).
hat does this mean for the pathophysiology of AF? As multiple
tudies clearly showed, the pathophysiology of lone AF is not equal
o AF in the presence of MVD; neither is paroxysmal AF
omparable to cAF (1).
A stunning finding of Boldt et al. (4) is the lack of substantial
xpression of AT1 in patients with SR (Fig. 2 of Boldt et al. [4]),
nown to be abundantly expressed by all cardiac cell types.
oreover, AT2 expression appears from that figure to be about
0 compared to AT1. Remarkably, both receptor subtypes have
he same protein size (52 kDa). The investigators claim to support
heir findings by immunohistologic analysis, which locates sites of
xpression rather than allowing quantification.
A direct comparison between left and right atrial tissue was not
erformed in a single patient. In sum, it remains unclear whether
he described differences in AT expression are solely due to the
resence or absence of AF or to the impact of present coronary
rtery/valve diseases.
What can we learn about receptor expression in AF? Expression
atterns are clearly time-dependent and, as observed for other
ignaling pathways, differences exist between right and left atria. In
atients with long-lasting AF (average 47 months in our study) a
eversal of AT1/AT2 expression may occur similar to ventricular
eceptor levels during heart failure, which is also characterized by
xtensive ventricular fibrosis (5). Sustained increase of peptide
ormone levels often down-regulates their receptor (5). Down-
egulation of AT1 may indeed follow an initial phase of up- pegulation. Thus, our previous results do “fit into the pathophys-
ology.” However, the time course of receptor expression has not
et been analyzed.
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EPLY
trial fibrillation (AF) is associated with electrical remodeling in
he human atria (1), and angiotensin II (AngII) is involved in the
rocess of atrial electrical remodeling (2). Recently, we analyzed
he expression of angiotensin II receptor type 1 (AT1) and 2 (AT2)
n the human left atrium and were able to show that AF is
ssociated with an up-regulation of AT1 in the human left atrium
3), but not in the human right atrium. Regarding the expression
f AT2 in the right atrium, we could show results similar to Goette
t al. (4); however, the results were less pronounced than in the
tudy of Goette et al. This might be caused by different patient
opulations. Furthermore, we could clearly demonstrate that an
nderlying mitral valve disease (MVD) did not have any significant
nfluences on the expression of AngII receptor subtypes (Fig. 4A to
D in Boldt et al. [3]). Other possible effects of an underlying
VD were not mentioned in our study.
Goette et al. (4) claimed a direct comparison between left and
ight atrial tissue in a single patient. For ethical reasons it was not
ossible to obtain atrial tissue samples of both atria of a single
atient, a fact that concerns most of the other study groups.
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June 16, 2004:2363–6owever, an animal model would provide results that may help to
nderstand pathophysiological mechanisms in AF.
In our study (3), we did not assert to use the immunological
nalysis for quantification. After finding clear histological differ-
nces (by visualization) between patients in sinus rhythm (SR) and
F, we quantified the expression of AT1 and AT2 by Western blot
echniques. We could detect a significant increase in AF compared
o SR in the AT1 expression, but not in the AT2 expression (Fig.
A [3]). As shown in Figure 2, there was a higher level of AT1 in
atients with both lone AF and MVD  AF compared to a lower
evel in patients with SR. In contrast to the claim of Goette et al.,
here was no lack of expression of AT1 in SR; however, a low level
Fig. 2 [3]).
We cannot exclude that other substrates or pathways may
nfluence the expression of AT1/AT2 in patients with AF. How-
ver, a time-dependent expression of AT1 has not yet been
nalyzed and is difficult to investigate in humans. In fact, differ-
nces exist in the expression of angiotensin II receptor subtypes
etween human left and right atrium. Furthermore, because AF
epends from the left atrium (5), it is important to consider both
tria to draw possible conclusions about pathophysiological influ-
nces of signaling pathways. Owing to our results, AF is associated
ith an upregulation of AT1 in the left atrium, but not in the right
trium. This suggests a pathophysiological role of AT1 in AF
3,6,7).
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ractice: Monitoring Transmyocardial
evascularization Use and Outcomes
onsidering the significant clinical experience with transmyocar-
ial revascularization (TMR) in both the controlled trial and
real-world” setting, we felt compelled to comment on the recent
etrospective registry report by Peterson et al. (1) culled from the
ociety of Thoracic Surgeons national cardiac database. Regarding
ole-therapy TMR, the investigators confirm findings observed in
ve prospective randomized trials comparing TMR to medical
herapy in “no option” class III/IV angina patients: like most new
echnologies, there is a learning curve, and surgical risk is increased
n sicker patients (2–6). Their commentary, similarly, is not new.
llen et al. (2) reported reduced operative mortality rate from 5%
verall to 2% in the last 100 randomized patients, attributable to
urgical technique refinement and patient selection; Frazier et al.
3) reported unstable angina as a significant predictor of operative
ortality. Others with clinical experience in treating unstable
atients (2,7,8) confirm that such patients without conventional
ptions represent a higher risk group for TMR.
Although not the intent of their retrospective study, Peterson et
l. (1) fail to summarize adequately the clinical benefits of
ole-therapy TMR. In prospective randomized trials at one year,
MR provided superior angina relief, decreased rehospitalizations,
nd improved exercise times compared to patients managed
edically. A recent five-year follow-up of randomized patients
emonstrated significantly increased Kaplan-Meier survival rates
nd sustained, significantly superior angina relief in patients
andomized to TMR compared to medical therapy (9).
As reported by the investigators (1), TMR is increasingly being
tilized adjunctively with coronary artery bypass grafting (CABG)
n patients with diffuse coronary artery disease (CAD) who would
e incompletely revascularized by CABG alone. In a prospective,
andomized trial involving 263 such patients, CABG/TMR pro-
ided operative and one-year mortality benefits with a trend
oward superior angina relief compared to CABG alone (10). The
etrospective report by Peterson et al. (1) compares patients in the
TS database who received CABG/TMR with a concocted
ontrol group consisting of CABG-only patients with triple-vessel
isease who received 3 grafts. The appropriateness of this
omparison is questionable, because it assumes that incomplete
evascularization in the control group occurred in an area of
schemic viable myocardium supplied by a diffusely diseased,
ngraftable coronary artery and that all participating centers
ccurately and consistently defined three-vessel disease. It is not
ossible to verify this by simply querying the STS database. It is
mportant also to note that surgeons are increasingly operating on
atients with diffuse-CAD, which has been shown to be a
owerful independent predictor of operative mortality (11,12).
nfortunately, the presence of diffuse-CAD is not factored into
he STS database or other national databases. Thus, such case-
atched comparisons against CABG/TMR-treated patients with
iffuse-CAD can be unreliable because control database sources
ail to account for diffuse-CAD and therefore underestimate pre-
icted operative mortality in this select patient group.
We applaud the investigators in supporting continued physician
raining and education regarding the judicious application of
ole-therapy TMR or adjunctively in patients who would be
ncompletely revascularized by CABG alone. Long-term
